Crosspoint Therapeutics
- Biotech or pharma, therapeutic R&D
Most of the antibody based therapeutics have toxicity issues arising from antibody Fc region with Fc gamma receptors expressed on normal cells such as immune cells. We developed a proprietary platform (called Stealth-Body) to eliminate these off-target toxicities, which we are using to develop ADCs with high therapeutic margins and agonistic immune stimulating drugs. We are currently looking for research collaboration based on our Stealth-Body platform or looking for investors for series-A investment
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}